Table 2.
Comparison of clinical outcomes between the BKVAN and control groups in kidney transplantation
| Variable | BKVAN group (n = 15) | Control group (n = 356) | P value |
|---|---|---|---|
| Biopsy-proven acute rejection | 10 (66.7) | 43 (12.1) | < 0.001 |
| Cause of graft failure | 10 | 43 | 0.095 |
| Acute rejection | 3 (30.0) | 5 (11.6) | |
| Chronic rejection | 5 (50.0) | 7 (16.3) | |
| Functioning allograft | 2 (20.0) | 23 (53.5) | |
| Recurrent glomerulonephritis | 0 | 6 (14.0) | |
| Infection | 0 | 2 (4.7) | |
| Cause of patient death | 5 | 26 | 0.487 |
| Cardiovascular disease | 1 (20.0) | 4 (15.4) | |
| Infection | 2 (40.0) | 15 (57.7) | |
| Cerebrovascular accident | 2 (40.0) | 2 (7.7) | |
| Hepatic failure | 0 | 1 (3.8) | |
| Malignancy | 0 | 1 (3.8) | |
| Others | 0 | 3 (11.5) | |
| Follow-up duration (mo) | 88.8 ± 57.9 | 99.0 ± 51.5 | 0.451 |
Values are expressed as number (%), number only, or mean ± standard deviation.
BKVAN, BK virus-associated nephropathy.